FDA Used Invokana Review To Reflect On Diabetes CV Risk Policy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Agency officials viewed the review of canagliflozin – the first program started after the 2008 outcomes trial requirement – as a chance to look at lessons learned since the policy went into effect.